Analysts Expect NxStage Medical, Inc. (NXTM) Will Post Quarterly Sales of $102.79 Million
Brokerages expect that NxStage Medical, Inc. (NASDAQ:NXTM) will announce sales of $102.79 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for NxStage Medical’s earnings. The lowest sales estimate is $102.36 million and the highest is $103.60 million. NxStage Medical posted sales of $91.95 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 11.8%. The company is expected to announce its next quarterly earnings report on Thursday, November 2nd.
According to Zacks, analysts expect that NxStage Medical will report full-year sales of $102.79 million for the current financial year, with estimates ranging from $399.98 million to $402.90 million. For the next year, analysts expect that the firm will report sales of $444.79 million per share, with estimates ranging from $436.45 million to $460.20 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for NxStage Medical.
NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.03). The business had revenue of $92.20 million for the quarter, compared to analysts’ expectations of $96.47 million. NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same period last year, the firm earned ($0.03) earnings per share.
Several research firms recently weighed in on NXTM. Jefferies Group LLC downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating and reduced their price target for the stock from $33.00 to $30.00 in a research report on Tuesday, August 8th. William Blair downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Monday, August 7th. Stephens downgraded shares of NxStage Medical from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $33.00 to $30.00 in a research report on Wednesday, August 9th. Zacks Investment Research upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a report on Thursday, August 10th. Finally, BTIG Research downgraded shares of NxStage Medical from a “buy” rating to a “neutral” rating in a report on Friday, August 11th. One analyst has rated the stock with a sell rating and eight have issued a hold rating to the company. NxStage Medical currently has an average rating of “Hold” and an average target price of $30.29.
In related news, President Joseph E. Turk, Jr. sold 1,000 shares of the stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $25.19, for a total transaction of $25,190.00. Following the completion of the transaction, the president now owns 75,903 shares of the company’s stock, valued at approximately $1,911,996.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Winifred L. Swan sold 3,500 shares of the stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $23.14, for a total transaction of $80,990.00. Following the transaction, the senior vice president now directly owns 17,270 shares of the company’s stock, valued at approximately $399,627.80. The disclosure for this sale can be found here. Insiders have sold a total of 53,900 shares of company stock valued at $1,429,518 in the last 90 days. Insiders own 4.70% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in NxStage Medical during the first quarter worth $140,000. Ameritas Investment Partners Inc. bought a new position in NxStage Medical during the first quarter worth $148,000. Quantitative Systematic Strategies LLC bought a new position in NxStage Medical during the second quarter worth $203,000. Amalgamated Bank boosted its position in NxStage Medical by 7.1% in the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock worth $210,000 after buying an additional 553 shares during the last quarter. Finally, Menta Capital LLC bought a new position in NxStage Medical during the first quarter worth $212,000. 91.82% of the stock is owned by hedge funds and other institutional investors.
Shares of NxStage Medical (NASDAQ NXTM) opened at 29.23 on Wednesday. NxStage Medical has a one year low of $20.45 and a one year high of $30.80. The company’s market capitalization is $1.93 billion. The stock has a 50 day moving average price of $25.26 and a 200 day moving average price of $25.88.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.